Drugs / ZYH7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01539616 | Nov 2011 → Jun 2012 | hyperlipidemia, hypertriglyceridemia | Zydus Lifesciences Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2007-08-30 | Zydus Lifesciences Limited | Regulatory Zydus Cadila files its 5th IND ZYH7 - a novel drug candidate for treating dyslipidemia and metabolic disorders zyduslife.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-08-30 | Zydus Lifesciences Limited | Zydus Cadila files its 5th IND ZYH7 - a novel drug candidate for treating dyslipidemia and metabolic disorders zyduslife.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYH7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01539616 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL3545093 ↗1“PPAR) alpha agonist” NCT01539616 ↗ |
| Route | Oral | “ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.” NCT01539616 ↗ |
| Target | PPARA | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL3545093 ↗ |